Reducing HIV-related stigma among young people attending school in Northern Uganda: study protocol for a participatory arts-based population health intervention and stepped-wedge cluster-randomized trial.

BACKGROUND: HIV-related stigma negatively impacts HIV prevention, treatment, and care, particularly among children and adolescents in sub-Saharan Africa. Interventions that are culturally grounded and relevant for addressing root causes may reduce the stigma experienced by HIV-positive and HIV-affected young people. This study, to be conducted in a post-conflict, rural setting in Omoro District, Uganda, will develop and evaluate a transformative  arts-based HIV-related stigma intervention rooted in local cultural knowledge to reduce stigma and improve HIV prevention and care for young people living with HIV. The intervention will be delivered to young people attending school by community Elders, with the support of teachers, through the transfer of local cultural knowledge and practices with the aim of re-establishing the important cultural and social role of Elders within a community that has suffered the loss of intergenerational transfer of cultural knowledge throughout a 25-year civil war. METHODS: A formative research phase consisting of interviews with students, teachers, and Elders will inform the intervention and provide data for study objectives. Workshops will be delivered to Elders and teachers in participating schools to build capacity for arts-based, educational workshops to be conducted with students in the classroom. The intervention will be evaluated using a stepped-wedge cluster-randomized trial. Government-funded schools in Omoro District will be randomized into three blocks, each comprised of two primary and two secondary schools (n=1800 students). Schools will be randomly assigned to a crossover sequence from control to intervention condition in 8-week intervals. A process evaluation will be implemented throughout the study to evaluate pathways between intervention development, implementation, and effects. DISCUSSION: This study will generate comprehensive, in-depth participatory research and evaluation data to inform an effective and sustainable protocol for implementing arts-based HIV stigma interventions for young people in school settings. Findings will have widespread implications in post-conflict settings for HIV prevention, treatment, and care. TRIAL REGISTRATION: ClinicalTrials.gov NCT04946071 . Registered on 30 June 2021.

HIV disease progression to CD4 count <200 cells/µL and death in Saskatoon, Saskatchewan.

OBJECTIVE: To characterize and identify determinants of HIV disease progression among a predominantly injection drug use (IDU) HIV population in the highly active antiretroviral therapy era. METHODS: The present retrospective study was based on 343 HIV patients diagnosed from 2005 to 2010 from two clinics in Saskatoon, Saskatchewan. Disease progression was defined as the time from diagnosis to immunological AIDS (CD4 count <200 cells/µL) and death. Uni- and multivariable Cox proportional hazards models were used. RESULTS: Of the 343 patients, 79% had a history of IDU, 77% were hepatitis C virus (HCV) coinfected and 67% were of Aboriginal descent. The one-year and three-year immunological AIDS-free probabilities were 78% and 53%, respectively. The one-year and three-year survival probabilities were 97% and 88%, respectively. Multicollinearity among IDU, HCV and ethnicity was observed and, thus, separate models were built. HCV coinfection (HR 2.9 [95% CI 1.2 to 6.9]) was a significant predictor of progression to immunological AIDS when controlling for baseline CD4 counts, treatment, age at diagnosis and year of diagnosis. For survival, only treatment use was a significant predictor (HR 0.34 [95% CI 0.1 to 0.8]). HCV coinfection was marginally significant (P=0.067). CONCLUSION: Baseline CD4 count, HCV coinfection, year of diagnosis and treatment use were significant predictors of disease progression. This highlights the importance of early treatment and the need for targeted interventions for these particularly vulnerable populations to slow disease progression.

OBJECTIF: Caractériser et établir les déterminants de la progression du VIH dans une population atteinte du VIH surtout composée d'utilisateurs de drogues injectables (UDI) à une époque d'antirétrovirothérapie très active. MÉTHODOLOGIE: La présente étude rétrospective s'est fondée sur 343 patients atteints du VIH diagnostiqués entre 2005 et 2010 dans deux cliniques de Saskatoon, en Saskatchewan. La progression de la maladie était définie comme le moment du diagnostic jusqu'à l'apparition du sida immunologique (numération de CD4 inférieure à 200 cellules/µL), puis jusqu'au décès. Les chercheurs ont utilisé le modèle univariable et multivariable de risques proportionnels de Cox. RÉSULTATS: Sur les 343 patients, 79 % avaient déjà été UDI, 77 % étaient co-infectés par le virus de l'hépatite C (VHC) et 67 % étaient d'origine autochtone. La probabilité de non-apparition de sida immunologique au bout d'un an et de trois ans correspondait à 78 % et à 53 %, respectivement. La probabilité de survie au bout d'un an et de trois ans s'élevait à 97 % et à 88 %, respectivement. Les chercheurs ont observé une multicolinéarité entre les UDI, le VHC et l'ethnie et ont donc préparé des modèles différents. La co-infection par le VHC (RC 2,9 [95 % IC 1,2 à 6,9]) était un prédicteur important de progression en sida immunologique lorsqu'on contrôlait l'effet de la numération de CD4 de référence, du traitement, de l'âge au diagnostic et de l'année de diagnostic. Seule l'utilisation du traitement était une prédicteur important de la survie (RC 0,34 [95 % IC 0,1 à 0,8]). La co-infection par le VHC avait peu d'importance (P=0,067). CONCLUSION: La numération de CD4 de référence, la co-infection par le VHC, l'année de diagnostic et l'utilisation d'un traitement étaient des prédicteurs importants de progression de la maladie. Ces constatations font ressortir l'importance d'un traitement rapide et la nécessité de procéder à des interventions ciblées pour ces populations particulièrement vulnérables afin de ralentir la progression de la maladie.